^
    CANCER:

    Triple Negative Breast Cancer





    Show legend
    Group by Gene:
    Include preclinical:

    pegylated liposomal doxorubicin
    		0
    Topoisomerase II inhibitor
    doxorubicin hydrochloride
    epirubicin
    pembrolizumab
    		1
    PD1 inhibitor
    toripalimab-tpzi
    tislelizumab
    2
    Tubulin polymerization promoter
    carboplatin
    atezolizumab
    		3
    PD-L1 inhibitor
    durvalumab
    avelumab
    4
    DNA synthesis inhibitor
    gemcitabine
    cisplatin
    5
    Thymidylate synthase inhibitor
    capecitabine
    6
    Tubulin polymerization inhibitor
    vinorelbine tartrate
    PARP inhibitor
    olaparib
    talazoparib
    		7
    PARP inhibitor
    niraparib
    pamiparib
    ABT-888
    rucaparib
    pembrolizumab + niraparib
    		8
    PD1 inhibitor, PARP inhibitor
    pembrolizumab + olaparib
    tislelizumab + pamiparib
    9
    PI3K inhibitor, AKT inhibitor
    RG7440
    CDK4 inhibitor + CDK6 inhibitor
    		10
    CDK4 inhibitor, CDK6 inhibitor
    trilaciclib
    palbociclib
    abemaciclib
    11
    Tubulin polymerization promoter, Bcl2 inhibitor
    paclitaxel
    carboplatin + paclitaxel
    12
    Androgen receptor inhibitor
    enzalutamide capsule
    darolutamide
    13
    PI3K inhibitor
    AN2025
    14
    PI3Kγ inhibitor
    IPI-549
    15
    CDK7 inhibitor
    CT7001
    YPN-005
    16
    VEGFR-2 inhibitor, PARP inhibitor
    rivoceranib + fluzoparib
    17
    PD-L1 inhibitor, PARP inhibitor
    olaparib + durvalumab
    18
    mTOR inhibitor
    everolimus
    19
    PD1 inhibitor, Multi-tyrosine kinase inhibitor
    camrelizumab + SHR 1020
    20
    Alkylating agent
    D19466
    21
    IL-6R antagonist
    tocilizumab
    22
    TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
    larotrectinib
    cetuximab
    		23
    EGFR inhibitor
    gefitinib
    erlotinib
    24
    HDAC inhibitor
    romidepsin
    panobinostat
    25
    RET inhibitor
    pralsetinib
    26
    VEGFR inhibitor, PD-L1 inhibitor, PARP inhibitor
    olaparib + durvalumab + cediranib
    27
    PIK3CA inhibitor, PARP inhibitor
    olaparib + alpelisib
    28
    CCR5 receptor antagonist, Viral entry inhibitor
    leronlimab
    29
    BET inhibitor, PARP inhibitor
    talazoparib + ZEN-3694
    30
    FGFR inhibitor
    futibatinib
    31
    PD-L1 inhibitor, VEGF-A inhibitor
    BNT327
    bevacizumab + atezolizumab
    32
    Tubulin polymerization promoter, Alkylating agent, Bcl2 inhibitor
    carboplatin + paclitaxel + cyclophosphamide
    33
    PD1 inhibitor, MEK inhibitor
    pembrolizumab + binimetinib
    34
    BRAF inhibitor, BRAF V600E inhibitor
    vemurafenib
    35
    WEE1 inhibitor
    AZD1775
    36
    PD-L1 inhibitor, CTLA4 inhibitor
    KN046
    37
    ALK inhibitor
    crizotinib
    ceritinib
    38
    PD1 inhibitor, CDK inhibitor
    pembrolizumab + MK-7965
    39
    HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    fam-trastuzumab deruxtecan-nxki
    40
    β-catenin inhibitor, CBP inhibitor, Microtubule inhibitor
    eribulin mesylate
    41
    PD-L1 inhibitor, MYC inhibitor
    PD-L1 inhibitor + MYC inhibitor
    42
    Immunotherapy
    Immunotherapy
    43
    CDK4 inhibitor, EGFR inhibitor, CDK6 inhibitor
    EGFR inhibitor + CDK4 inhibitor + CDK6 inhibitor
    erlotinib + palbociclib
    44
    B7-H3-targeted antibody-drug conjugate
    B7-H3-targeted antibody-drug conjugate
    45
    EGFR-targeted antibody-drug conjugate
    EGFR-targeted antibody-drug conjugate
    46
    HDAC inhibitor, AKT1 inhibitor
    HDAC inhibitor + AKT1 inhibitor
    47
    HDAC inhibitor, AKT2 inhibitor
    HDAC inhibitor + AKT2 inhibitor
    48
    Chemotherapy
    TC
    CaT
    49
    Microtubule stabilizer, Tubulin polymerization promoter
    carboplatin + docetaxel
    docetaxel
    50
    TROP-2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    sacituzumab govitecan-hziy
    MK-2870
    51
    B7-H4-targeted antibody-drug conjugate, Tubulin inhibitor
    XMT-1660
    52
    PD-L1 inhibitor, Multi-tyrosine kinase inhibitor
    anlotinib + APL-502
    53
    HER2 inhibitor, EGFR inhibitor
    lapatinib
    54
    TSP1 stimulant, CD36 stimulant
    VT1021
    55
    Chk1 inhibitor, Chk2 inhibitor
    ACR-368
    56
    PD-L1 inhibitor, Immunostimulant
    atezolizumab + RG6180
    57
    Microtubule stabilizer, Tubulin polymerization promoter, Sortilin inhibitor
    TH 1902
    58
    GPNMB-targeted antibody-drug conjugate, Microtubule inhibitor
    CDX-011
    59
    Lyase inhibitor, Androgen receptor antagonist
    TAK 700
    60
    HER2 inhibitor, HER4 inhibitor, EGFR inhibitor
    neratinib
    trastuzumab + neratinib
    61
    Topoisomerase II inhibitor, Alkylating agent
    doxorubicin hydrochloride + cyclophosphamide
    cyclophosphamide + epirubicin
    62
    Topoisomerase II inhibitor, Tubulin polymerization promoter, Bcl2 inhibitor
    carboplatin + paclitaxel + non-pegylated liposomal doxorubicin
    carboplatin + paclitaxel + doxorubicin hydrochloride
    63
    β-catenin inhibitor, CBP inhibitor, PD1 inhibitor, Microtubule inhibitor
    pembrolizumab + eribulin mesylate
    64
    HER3-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    U3-1402
    65
    PD-L1 inhibitor, HER2-targeted antibody-drug conjugate, Microtubule inhibitor
    atezolizumab + ado-trastuzumab emtansine
    66
    Microtubule inhibitor, TROP-2-targeted antibody-drug conjugate
    BAT8003
    LCB84
    67
    MEK inhibitor
    trametinib
    selumetinib
    68
    AKT inhibitor
    GSK690693
    69
    γ-secretase inhibitor
    nirogacestat
    70
    BET inhibitor
    JQ-1
    71
    Tubulin polymerization promoter, DNA synthesis inhibitor, Bcl2 inhibitor
    cisplatin + paclitaxel
    72
    p53 stimulant
    COTI-2
    73
    ERK2 inhibitor, PI3K inhibitor, ERK inhibitor, ERK1 inhibitor, GnRH agonist
    triptorelin + AEZS 136 + AEZS-134
    74
    PI3K inhibitor, ERK inhibitor, GnRH agonist
    triptorelin + AEZS-129
    75
    GnRH agonist, AKT inhibitor
    triptorelin + D21266
    76
    GnRH agonist
    triptorelin
    77
    HER2 inhibitor, HER4 inhibitor, EGFR inhibitor, PARP inhibitor
    neratinib + niraparib
    olaparib + neratinib
    78
    PARP1 inhibitor
    AZD5305
    79
    ADAM9-targeted antibody-drug conjugate, Microtubule inhibitor
    IMGC936
    80
    EGFR inhibitor, CD16A agonist
    AFM24
    81
    ATM kinase inhibitor
    AZD1390
    82
    Annexin A1 inhibitor
    MDX-124
    83
    β-catenin inhibitor, CBP inhibitor, Wnt signalling pathway inhibitor
    PRI724
    84
    CDK4 inhibitor, CDK6 inhibitor, PARP inhibitor
    olaparib + palbociclib
    talazoparib + abemaciclib
    85
    TTK inhibitor
    VRN08
    86
    PARP inhibitor, WEE1 inhibitor
    niraparib + AZD1775
    olaparib + AZD1775
    87
    XPO1 inhibitor
    selinexor
    88
    PD-L1 inhibitor, CD73 inhibitor
    durvalumab + MEDI9447
    89
    Microtubule inhibitor, EGFR-targeted antibody-drug conjugate
    LR004-VC-MMAE
    HTI-1511
    90
    PI3K inhibitor, PARP inhibitor, FAK inhibitor, AKT inhibitor
    talazoparib + LY294002
    91
    ATR inhibitor, PARP inhibitor
    olaparib + AZD6738
    92
    NEDD8 activating enzyme inhibitor
    MLN4924
    93
    β-catenin inhibitor, DNA synthesis inhibitor, CBP inhibitor, Microtubule inhibitor
    gemcitabine + eribulin mesylate
    94
    TGM2 inhibitor
    MD102
    95
    Androgen receptor antagonist
    HC-1119
    apalutamide
    96
    DOT1L inhibitor
    EPZ-5676
    97
    CDK19 inhibitor, CDK8 inhibitor
    RVU120
    98
    PTK7-targeted antibody-drug conjugate, TROP-2-targeted antibody-drug conjugate
    BCG033
    99
    Androgen receptor inhibitor, ALK inhibitor
    enzalutamide capsule + ceritinib
    100
    p53 reactivator
    APR-246
    101
    USP1 inhibitor, PARP inhibitor
    olaparib + RG6614
    102
    Androgen receptor inhibitor, CDK7 inhibitor
    enzalutamide capsule + KRLS-017
    103
    ATR inhibitor, TROP-2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    sacituzumab govitecan-hziy + BAY 1895344
    104
    CDK19 inhibitor, mTOR inhibitor, CDK8 inhibitor
    everolimus + SNX-631
    105
    B7-H4-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    AZD8205
    106
    Microtubule inhibitor, CD228-targeted antibody-drug conjugate
    SGN-CD228A
    107
    MERTK-targeted antibody-drug conjugate
    RGX-019
    108
    MUC1-targeted antibody-drug conjugate, Microtubule inhibitor
    3D1-MMAE
    109
    MERTK-targeted antibody-drug conjugate, Microtubule inhibitor
    RGX-019-MMAE
    110
    Nectin-4-targeted antibody-drug conjugate, Microtubule inhibitor
    9MW2821
    111
    MNK1 degrader, MNK2 degrader
    VNLG-152R
    112
    LIF inhibitor
    EC359
    113
    JNK inhibitor
    JNK-IN-8
    114
    VEGFR inhibitor, PDGFR inhibitor, ALK inhibitor, c-KIT inhibitor
    crizotinib + sunitinib
    115
    mTOR inhibitor, EGFR inhibitor
    gefitinib + everolimus
    116
    PI3Kβ inhibitor
    AZD8186
    117
    DNA replication inhibitor, Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor, EGFR-targeted antibody-drug conjugate
    ABT 263 + ABBV-321
    118
    Microtubule inhibitor, Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor, EGFR-targeted antibody-drug conjugate
    ABT 263 + ABT-414
    119
    LAMP1-targeted antibody-drug conjugate, Microtubule inhibitor
    SAR428926
    120
    Ribonucleotide reductase inhibitor
    NSC-324360
    121
    FAK inhibitor
    VS-4718
    122
    DNA replication inhibitor, ROR1-targeted antibody-drug conjugate
    NBE-002
    123
    Aurora kinase inhibitor
    ENMD-2076
    No biomarker
    BRCA2 mutation
    BRCA2 5396insC
    PD-L1 expression
    PD-L1 overexpression
    TMB-H + PD-L1 expression
    PD-L1 negative
    PD-L1 underexpression
    PD-L1 amplification
    MSI-H/dMMR + PD-L1 expression
    BRCA1 mutation
    BRCA1 307 T> A (L63*)
    BRCA1 promoter methylation
    BRCA1 5396insC
    BRCA1 L1780P
    BRCA1 deletion
    BRCA1 3363delGAAA
    PTEN mutation
    AKT1 mutation
    PTEN K237fs
    AKT1 E17K
    AKT1 amplification
    PTEN-L
    AKT1 overexpression
    PTEN V85
    PTEN deletion
    BRCA wild-type
    AR positive
    HER-2 mutation
    HER-2 L755S
    HER-2 underexpression
    HER-2 negative
    AR overexpression
    AR underexpression
    HRD
    ERBB3 overexpression
    CDKN2A mutation
    CDKN2B mutation
    EGFR mutation
    EGFR expression
    TP53 mutation
    EGFR amplification
    TP53 R209fs*
    TP53 D281E
    EGFR overexpression
    TP53 R273H
    TP53 expression
    PIK3CA mutation
    TMB-H
    TMB-L
    CD8-H
    PIK3CA wild-type
    CCR5 expression
    CD8 positive
    CCR5 positive
    CFAP58 mutation
    HR positive
    BRAF V600E
    SORT1 expression
    GPNMB overexpression
    FGFR2 amplification
    TLE3 expression
    PALB2 mutation
    CD47 overexpression
    CD36 overexpression
    MMP17 expression + EGFR expression + RB1 expression
    PD-L1 expression + CD68 positive
    ATRX mutation
    PPM1D mutation
    PARP10 mutation
    EMSY mutation
    MSH6 mutation
    MYC expression
    miR-142 overexpression
    RB1 mutation
    CACNA1S mutation
    KPRP mutation
    L1CAM mutation
    SDK2 mutation
    PCDHA1 mutation
    COL22A1 mutation
    COL4A5 mutation
    ANXA6 underexpression
    RAD51 underexpression
    PD-L2 overexpression
    CTLA4 overexpression
    PD-1 overexpression
    HRD + BRCA wild-type
    CD38 expression
    PSIP1 expression
    CXCL12-L
    FOXP3 overexpression
    CD4 overexpression
    FCRL1 overexpression
    FSIP1 overexpression
    IGHG1 overexpression
    DNMT3A mutation
    ZNF689 underexpression
    BRCA1 mutation + RAD51B deletion
    ALK fusion
    BAP1 R300Gfs*6 + PD-L1 expression
    ETV6-NTRK3 fusion
    ETV6-NTRK3 fusion + CRTC3-NTRK3 fusion
    CCDC6-RET fusion
    SORT1 positive
    RB1 negative
    MYC overexpression
    MYC amplification
    MYC mutation
    GeparSixto immune signature
    DDR signature score
    TROP2 overexpression
    DDR
    High NLR
    Low NLR
    Choline elevation
    Low PLR
    14-gene IGG signature overexpression
    AR-regulated gene expression pathway signature
    CREBBP mutation
    GNRHR expression
    TLS gene signature
    HLA-E mutation
    KLF8 overexpression
    MCL1 amplification
    H3F3C mutation
    FGF23 mutation
    ADAM9 overexpression
    SNHG16 mutation
    CYP2D6 deletion
    ANXA1 overexpression
    BOP1 overexpression
    GNAS mutation
    CD276 overexpression
    BCL2L1 mutation
    LAG3 mutation
    CCNE1 overexpression
    miR-503-5p overexpression
    miR-34a expression
    TUSC7 overexpression
    CCND2 mutation
    SESN1 mutation
    USP18 overexpression
    ER positive
    TGM2 overexpression
    LIG1 deletion
    PKD1 mutation
    FER overexpression
    ALDH1A1 positive
    KMT2D mutation
    SMARCA4 mutation
    CXCR4 overexpression
    SOX2 overexpression
    KIF11 overexpression
    CD24 expression
    GJA1 expression
    SOX9 expression
    LINC00667 overexpression
    EPCAM expression
    TROP2 positive
    LDH elevation
    ACAT1 overexpression
    VTCN1 underexpression
    MELTF overexpression
    PTK7 expression + TROP2 expression
    BRCA2 mutation + RB1 deletion
    BRCA1 mutation + RB1 deletion
    MERTK expression
    TP53 R280K + BRCA wild-type
    EGFR overexpression + KRAS 13D
    MUC1 expression
    NECTIN4 overexpression
    TROP2 expression
    LAMP1 expression
    ROR1 expression
    FOXA1 overexpression
    PTK7 expression
    HR negative + EGFR amplification
    NOTCH2 mutation
    PTPN12 deletion
    CCL2 elevation
    LIFR expression
    CACNA1D E953D
    MDM2 amplification
    FOXC1 expression
    MFI2 expression
    FERMT1 expression
    ST14 expression
    DEDD overexpression
    NF2 negative
    CD73 elevation
    DUSP6 expression
    AKT3 expression
    NOTCH1 mutation
    GFRA1 overexpression
    CREBBP deletion